Page History

...

Synonyms matching the FSN are not required. 

Concentration strength units

For solids and semi-solids, a concentration strength will be mass/mass (weight/weight) – usually mg/g.

• Solid = pill, tablet, suppository, tape, patch, lozenge, implant, gum, capsule, etc.
• Semi-solid = cement, cream, gel, ointment, paste, poultice

For liquids, a concentration strength will be mass/volume (weight/volume) – usually mg/mL.

• Liquid = solution, suspension, tincture, spirit, emulsion, foam, lotion, oil, lacquer, etc.

International Unit

International Unit as a description is arbitrary, and to be understood, each product requires reference to a particular bioefficacy specification for that entity.  Therefore, international unit is neither a meaningful nor comparable description at Clinical Drug level.  International unit will be represented as unit in Clinical Drug descriptions.  Abbreviations will not be used.

...

The |Has presentation strength numerator unit| will still continue to have a value of |International unit (qualifier value)| even though unit is stated in the FSN and PT.

Product strength

...

not equal to

...

Concepts with product strength that is "not equal to" are modeled as primitive, with attributes added as described in the corresponding subpages, except that strength numerator attributes will not be added.  The appropriate Medicinal Product Form-only (MPF-only) concept will infer as a parent.

...

Concepts containing pancreatic enzymes are modeled based on the discrete enzymes; because of variability between real clinical drugs, synonyms representing a total amount in a particular product will not be included in the International Release.

Inference based on dose form

Clinical drugs containing precisely x are modeled with a count based on the substance(s) to support a closed world view (i.e., a count of 1 will not infer a count of 2).  The closed world view does not apply to dose forms.  A very rare case can arise where, for example, a clinical drug that is for an x ear and eye drop is a subtype of both the clinical drug x eye drop and the clinical drug x ear drop.  This makes real world sense where all descendants of x clinical drug eye drop are for use in the eye, and a small subgroup of them may also be acceptable for use in the ear.

For example,

Anhydrous

1220547004 |Product containing precisely gentamicin (as gentamicin sulfate) 3 milligram/1 milliliter conventional release eye drops (clinical drug)| correctly infers a subtype of 1142217003 |Product containing precisely gentamicin (as gentamicin sulfate) 3 milligram/1 milliliter conventional release ear and eye drops (clinical drug)|.

Anhydrous

When a clinical drug has a BoSS specified in a If the clinical drug strength specified in the Summary of Product Characteristics is based on as an anhydrous substance, then the BoSS PAI is represented as the anhydrous unmodified substance, and if supported by the referenced SPC, the PAI is i.e., the substance with an unspecified level of hydration. 

For example,

• • 1153520006 |Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 250 milligram/1 each conventional release oral tablet (clinical drug)|
  • BoSS = Carbidopa anhydrous
  PAI = Carbidopa

The SPC states each tablet "contains 27.0 mg carbidopa (equivalent to 25 mg of anhydrous carbidopa) and 250 mg levodopa."  The BoSS is anhydrous carbidopa, so the PAI is Carbidopa.  

• • 1331919008 |Product containing precisely carbidopa anhydrous (as carbidopa) 12.5 milligram and entacapone 200 milligram and levodopa 50 milligram/1 each conventional release oral tablet (clinical drug)|

This SPC states, "Each film-coated tablet contains 50 mg of levodopa, 12.5 mg of carbidopa anhydrous (as 13.5 mg carbidopa monohydrate) and 200 mg of entacapone."  The Boss is anhydrous carbidopa, so the PAI is Carbidopa.